Journal of Cancer Research and Therapeutics

Scope & Guideline

Fostering collaboration for a cancer-free future.

Introduction

Explore the comprehensive scope of Journal of Cancer Research and Therapeutics through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Journal of Cancer Research and Therapeutics in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0973-1482
PublisherWOLTERS KLUWER MEDKNOW PUBLICATIONS
Support Open AccessNo
CountryIndia
TypeJournal
Convergefrom 2005 to 2024
AbbreviationJ CANCER RES THER / J. Canc. Res. Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressWOLTERS KLUWER INDIA PVT LTD, A-202, 2ND FLR, QUBE, C T S NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra 400059, INDIA

Aims and Scopes

The Journal of Cancer Research and Therapeutics focuses on the latest advancements in cancer research, therapeutic strategies, and clinical practices. It serves as a platform for disseminating innovative findings that enhance understanding and treatment of cancer, while also addressing the multifaceted challenges faced by oncology professionals.
  1. Clinical Trials and Therapeutics:
    The journal emphasizes the reporting of clinical trials and therapeutic interventions across various cancer types, providing insights into efficacy, safety, and patient outcomes.
  2. Molecular and Cellular Biology of Cancer:
    Research on the molecular mechanisms underlying cancer development and progression is a core focus, including studies on genetic mutations, signaling pathways, and tumor microenvironment interactions.
  3. Radiotherapy and Interventional Techniques:
    The journal includes research on advancements in radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT) and brachytherapy, as well as interventional approaches like ablation and chemoembolization.
  4. Cancer Epidemiology and Prevention:
    Epidemiological studies exploring risk factors, prevention strategies, and population-based cancer trends are highlighted to inform public health initiatives.
  5. Innovative Diagnostic Approaches:
    The journal covers novel diagnostic techniques, including imaging advancements and biomarker discovery, that aid in the early detection and accurate characterization of tumors.
  6. Patient Care and Quality of Life:
    Research addressing the psychosocial aspects of cancer care, including quality of life assessments and supportive care strategies, is integral to the journal's scope.
The Journal of Cancer Research and Therapeutics has witnessed emerging themes that reflect the dynamic nature of cancer research, driven by technological advances and changing patient needs. These trends highlight the journal's commitment to addressing contemporary challenges in oncology.
  1. Immunotherapy and Personalized Medicine:
    There is a growing emphasis on research related to immunotherapy approaches and personalized treatment plans tailored to individual genetic profiles, reflecting a paradigm shift in cancer treatment.
  2. Molecular Targeted Therapy:
    Studies focusing on targeted therapies that inhibit specific molecular pathways are increasingly prominent, showcasing advancements in drug development and efficacy.
  3. Artificial Intelligence and Machine Learning in Oncology:
    The integration of AI and machine learning techniques in cancer diagnosis, treatment planning, and outcome prediction is a rapidly emerging area, enhancing the precision of oncology practices.
  4. Cancer Genomics and Biomarkers:
    Research into cancer genomics, including the identification of biomarkers for early detection and therapeutic response, is on the rise, facilitating advancements in precision oncology.
  5. Quality of Life and Patient-Centered Care:
    There is an increasing focus on research that evaluates the quality of life for cancer patients, addressing the psychosocial aspects of treatment and survivorship.
  6. Novel Therapeutic Delivery Systems:
    Emerging studies on innovative drug delivery systems, such as nanoparticles and nanocarriers, are gaining traction as they promise to enhance the efficacy of cancer therapies.

Declining or Waning

While the Journal of Cancer Research and Therapeutics continues to evolve, certain research areas have experienced a decline in focus. This shift may reflect changes in scientific interest, advancements in technology, or the emergence of more pressing issues in cancer research.
  1. Traditional Chemotherapy Studies:
    Research specifically focused on traditional chemotherapy regimens has waned, possibly due to the increasing interest in targeted therapies and immunotherapies that offer improved outcomes.
  2. Single-Agent Studies:
    There has been a noticeable decrease in studies evaluating the efficacy of single-agent therapies, as the trend shifts towards combination therapies that leverage synergistic effects.
  3. Basic Science Research on Common Cancer Types:
    Basic research on well-characterized cancer types (e.g., breast, lung) has reduced, as researchers increasingly explore rarer malignancies or investigate complex interactions in tumor biology.
  4. Conventional Imaging Techniques:
    The reliance on conventional imaging modalities for cancer diagnosis is declining, as advanced techniques such as molecular imaging and radiomics gain prominence.
  5. Palliative Care Research:
    While still important, the volume of research specifically focused on palliative care strategies has decreased, possibly overshadowed by curative treatment advancements.

Similar Journals

MOLECULAR CANCER RESEARCH

Innovating Cancer Research for Tomorrow's Therapies
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

CANCER GENE THERAPY

Innovating Genetic Solutions for Oncology
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Nature Reviews Clinical Oncology

Shaping the Future of Oncology with Evidence
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Molecular and Clinical Oncology

Innovating cancer care through rigorous research.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

CURRENT CANCER DRUG TARGETS

Innovating drug discovery at the forefront of cancer research.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Oncology Letters

Elevating Oncology Discourse for Better Patient Outcomes
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

MOLECULAR CANCER THERAPEUTICS

Elevating the standards of cancer therapeutics.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

Translational Cancer Research

Pioneering new frontiers in translational oncology.
Publisher: AME PUBLISHING COMPANYISSN: 2218-676XFrequency: 12 issues/year

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

Cancer Research Communications

Bridging gaps in cancer knowledge and practice.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

ONCOLOGY RESEARCH

Elevating Knowledge in the Fight Against Cancer
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.